Latest Breaking News On - Ashfield medcomms - Page 1 : comparemela.com

Hotter Temperatures May Heighten Headaches in Migraine Sufferers

As temperatures rise, so do chances for migraine attacks, according to a new study from a team of researchers at the University of Cincinnati College

United statesSan diegoNew yorkEli lillyFred cohenYing zhangVincent martinNiamh scottAshfield medcommsAl peterlinLaura colbranMario ortegaUc college of medicineTeva pharmaceuticals united states incErrex incAmerican headache society

Only Four Weeks Until Creative Tech Europe 2024: A Gathering of Creative Technologists in London

There are just four weeks to go until creative production leaders, technologists, and decision-makers in brands, agencies, and other industry players

Jarrod gingrasHenry stewartCharles duncanAshfield medcommsClair carter ginnAndre le masurierDavid russellPartner at forecast agencyTechnology meets human artistryCreative technology stackCreative technologyReal story groupTommy hilfigerCreative tech europeHighlights includeManaging director

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients .

Comunidad autonoma de catalunaFrance generalIsrael generalRodryg ramlauAshfield medcommsEnriqueta felipEnric carcerenyZahir rajiwateEric pichonBiomarcadoresy medicinaLinda basseChemother pharmacolTariq sethiAlison mackinnonPia jensenBertil lindmark

MM+M reveals its 2023 Awards finalists

The medical marketing industry’s biggest night of the year is scheduled for October 5 at Cipriani Wall Street.

United statesRush universityNew yorkMegan driscollCoherus biosciencesA whitney cummingsDenise henryLippe taylorDaiichi sankyoMike rosichLarry dobrowTop dogNovartis genentechTerri sandy aspercremeSanofi regeneronNeurocrine biosciences